Loading...
Loading...
Investing is risky. You might not know what you'll earn, it could be hard to sell, you might own less, unexpected things can happen, and you could lose all your money.
Jardin Pharma Berhad
Jardin Pharma Berhad (JPB) (1418172-K) was incorporated in Malaysia under the Companies Act 2016 on 11th May 2021 as a public company. JPB exists to fill the gap in the pharmaceutical industry and to deliver halal, innovative, effective, safe and eco-conscious pharmaceuticals, nutraceuticals and cosmeceuticals that are proudly made in Malaysia. JPB takes pride in combining nature and science to create novel products using cutting-edge technology. JPB aims to be the world's leader in Halal eco-pharmaceutical brands. JPB is undeniably dedicated to the health and vitality of your whole family.
Jardin Pharma Berhad (JPB) (1418172-K) was incorporated in Malaysia under the Companies Act 2016 on 11th May 2021 as a public company. JPB exists to fill the gap in the pharmaceutical industry and to deliver halal, innovative, effective, safe and eco-conscious pharmaceuticals, nutraceuticals and cosmeceuticals that are proudly made in Malaysia. JPB takes pride in combining nature and science to create novel products using cutting-edge technology. JPB aims to be the world's leader in Halal eco-pharmaceutical brands. JPB is undeniably dedicated to the health and vitality of your whole family.
MIN INVESTMENT
RM 2,500
MIN TARGET
RM 1,000,000
MAX TARGET
RM 10,000,000
DIVIDEND
8% to 10% p.a.
SHARE TYPE
Redeemable Convertible Preference Shares
TENURE
3 years
SHARE PRICE
RM 1
Understanding the Risks - Key Disclosures for ECF Investors into Jardin Pharma Berhad In September of 2022 Jardin Pharma Berhad (Jardin) acquired 100% of Xorix Sdn Bhd (Xorix), a troubled pharmaceutical manufacturing company that has the rare distinction of possessing Skim Anak Angkat (issued by the Ministry of Finance). In addition to all the other regulatory requirements needed to manufacture and supply certain pharmaceutical products to the Ministry of Health. Under this adoption scheme, Xorix has privileges and more access in providing a wider range of pharmaceutical products to the Ministry of Health. Though your investment would be in Jardin, it is the intention of the management to utilize the funds raised, for improving the performance and unlocking the value of Xorix. To navigate this, the new management has to address some financial issues, specifically an existing debt with SME Bank. The amount in question now stands at RM6 million as Jardin has successfully negotiated it down from an original outstanding amount of RM15 million. The funds were utilized to purchase machines and equipment for an additional production line. The new management has entered into discussions (still ongoing), with the bank, to restructure this reduced debt amount. . The new management is of the view, given the current positive business environment, growing demand, and unlocked potential with Skim Anak Angkat, that the opportunity for Xorix, and hence Jardin, lies in getting the additional production line running as soon as possible to increase its revenue thus allowing for the comfortable servicing of all obligations. To support this assertion is that since the acquisition, and still running on just one production line, Xorix has increased its capacity by more than 170%, whilst obtaining the approval from the Ministry of Health for the production of an additional 5 SKU’s which would significantly increase revenue based on initial indicated orders. What we have also noted is that under the new management of Jardin, active efforts are being made to enhance governance and reporting procedures of Xorix. This includes a focus on improving transparency and accuracy in financial reporting. Jardin is working closely with its auditors to ensure that the 2022 audited financial statements provide a true and fair view of the company's financial position. Key Disclosures Specifically, we would like to draw your attention to the risks associated with this investment. Firstly, based on representation by the Issuer, the funds raised from ECF will be fully utilized 100% by Xorix for the purpose of operationalizing the new production line to meet the new orders the company continues to obtain. Key to the success of this plan would be the successful negotiations with SME Bank on the debt restructuring. Secondly, we note an Auditor's Disclaimer of Opinion on 2021 Audited Financial Statement and hence before the company was acquired. Again, the new management is taking steps to address all matters with regards to the financial health of the company as has engaged an experienced Finance Director to lead these efforts. We nonetheless still encourage you to carefully review all available information, including the Issuer's business plan, financial statements, and any other relevant documents, before committing any funds. In case of any doubts or queries, please do not hesitate to reach out to us or seek independent professional advice.
Jardin Pharma Berhad (JPB) (1418172-K) was incorporated in Malaysia under the Companies Act 2016 on 11th May 2021 as a public company. JPB exists to fill the gap in the pharmaceutical industry and to deliver halal, innovative, effective, safe and eco-conscious pharmaceuticals, nutraceuticals and cosmeceuticals that are proudly made in Malaysia. JPB takes pride in combining nature and science to create novel products using cutting-edge technology. JPB aims to be the world's leader in Halal eco-pharmaceutical brands. JPB is undeniably dedicated to the health and vitality of your whole family.
Malaysia is an upper middle-income country that is a highly attractive investment destination for the life sciences and healthcare sector, which can be broadly divided into four categories, namely pharmaceuticals, biotechnology, healthcare, and medical devices. However, according to the United Nations COMTRADE database on international trade, Malaysia is still a net importer of pharmaceutical products with an import value of US$2.74 billion in 2021, and the share of local manufacturers of generic drugs is only 30%, insufficient to meet market demand, while the rest is covered by imports (ASEAN Briefing, 2023). Malaysian drug manufacturers are highly dependent on imported active pharmaceutical ingredients (APIs), excipients, and even packaging materials to formulate drugs.
To remain competitive, they are expanding their capacity in the niche segment of halal pharmaceuticals. However, the halal pharmaceutical industry involves complex supply chains and manufacturing processes that require strict compliance with halal standards, which can be a time-consuming and costly process. In addition, Malaysian pharmaceutical manufacturers are small in terms of sales compared to multinational corporations (MNCs) that import medicines into Malaysia. MNCs from developed countries also do not have manufacturing facilities in Malaysia. Small and medium-sized pharmaceutical companies typically have difficulty accessing financing, which can limit R&D activities, product development, and business growth. Malaysian pharmaceutical manufacturers also produce generic drugs instead of patent-protected originator drugs because the technology to produce a new drug is limited.
We research, develop, manufacture and distribute Halal-certified pharmaceuticals, nutraceuticals and cosmeceuticals by using locally sourced botanical ingredients to formulate our own Malaysian-made products. We also provide OEM contract services to help other local Malaysian companies manufacture their own brand of pharmaceuticals, nutraceuticals and cosmeceuticals. To achieve this, we employ highly qualified local scientists, pharmacists, medical professionals and sales managers who understand the global halal pharmaceutical market. We also work closely with local and international suppliers to provide gold-standard medicines for the local market gaps
Our subsidiary company, Xorix Sdn. Bhd. is one of the biggest skin OTC product manufacturers in Malaysia. Instead of using chemical synthesis, we mainly use locally sourced plant-based ingredients to formulate our halal pharmaceutical products using the company's expertise in galenical pharmacy. Xorix Sdn. Bhd. also becomes the first halal-certified bumiputera-owned pharmaceutical company that formulates Paracetamol syrup and suspension. Currently, there are nine pharmaceutical products in our R&D pipelines. JPB also is building the first halal bacterial farm and Liposomal centre in Malaysia as a result of a strategic collaboration with IIUM and UTM
Our main business model is direct sales to both public and private hospitals, clinics, and pharmacies. Our company was selected by the Ministry of Health Malaysia to be one of the bumiputera companies that was adopted into MOH scheme to distribute pharmaceuticals to the MOH facilities throughout Malaysia, as part of MOH’s initiative to boost business growth of local Malaysian pharmaceutical manufacturers.
We also offer a merchant program to owners of private hospitals, clinics and pharmacies who can sell our products at their brick-and-mortar stores and affiliate program to individuals who don’t own a store but can sell our products by using direct selling or dropshipping models. We also have our own WebApp platform, Herbitus.com to sell our products directly to our customer base. To enter the export market, we collaborate with various global institutions like WHO and UNICEF and with international distributors to sell our products to other countries. As to date, we have signed multiple Memorandums of Understanding (MoUs) with international distributors from Kenya, Indonesia, Brunei, Maldives, Cambodia, Macao and Kingdom of Saudi Arabia to strengthen JPB's export portfolios.
Malaysia has been globally recognized for having pioneered the halal standards and certification scheme since the early 70s. Malaysia also is the market leader in halal pharmaceuticals after being a pioneered country to establish a new Halal Pharmaceutical Standard (MS2424:2012). This standard allows pharmaceutical product manufacturers to apply for halal certification and established fundamental standards for the manufacturing and handling of goods, including pharmaceutical products in finished dosage forms, including both prescription and over-the- counter medicines for human use (examples include biopharmaceuticals, traditional medicines, and investigational medicines) that are registered with the Drug Control Authority, Ministry of Health. According to Adroit Market Research (2023), the global halal pharmaceutical market will reach USD174.59 billion by 2025 with Asia Pacific as the region with the largest Muslim population.
An aging population, rising non-communicable diseases including diabetes, hypercholesterolemia, and hypertension, as well as other related medical disorders, are driving up demand for pharmaceuticals in Malaysia. The Malaysian pharmaceutical market was valued at USD2.9 billion in 2020, per a recent analysis by Global Data (2022). From 2013 to 2020, the market increased ata CAGR of more than 9% with generic, biologic, biosimilar, and over-the-counter (OTC) medications being the major product categories. Under KKM Adoption scheme, Jardin Pharma Berhad is given a priority to supply pharmaceutical products to the government health facilities throughout Malaysia. Government annual procurement is up to RM2.3 billion.
Group CEO
Experience
2019 - Present
2016 - Present
Nov 2014 - Aug 2016
March 2014 - Nov 2014
March 2012 - March 2014
Education:
2020 - Present
2006 - 2011
COO
An engineer with more than 10 years experience in running businesses. He has built and ran multiple companies in personal care, healthcare and pharmaceutical sectors. He is also an expert in global sourcing, industrial machineries setup and lean operations.
Experience:
2016 - Present
Education:
2011 - 2017
CONSULTANT
An academician with 24 years of working experience in healthcare, pharmaceutical, research and development. He has been working with two top pharmaceutical companies in ASEAN since 2006, and has been appointed as a Pharma Auditor Associate by SQA Los Angeles, United States. He has a certification in international project management (CIPM) in healthcare project and business development.
Experience:
Education:
1997
2004
2007
2010
2014 - present
Head of Sales
A pharma sales expert with 2 years of working experience as a Senior Sales Manager at ROCHE Malaysia and 9 years of working experience as a Senior Manager at International Sales Department of Pharmaniaga Berhad.
Experience:
2022 - Present
2013 - 2022
2011 - 2013
Senior Sales Manager | Roche Pharma
Education
1994 - 1996
General Manager of Business Development
A global pharma sales expert with 7 years of working experience with the World Health Organization (WHO) in managing procurement of pharmaceuticals, vaccines, kits & diagnostics for WHO Country Offices, worth at USD25 million. He also has a solid 7 years of experience as a Senior Regulatory Affairs Manager at Roche Malaysia Sdn Bhd with a responsibility to register and handle regulatory matters for ROCHE pharmaceutical products that covers ASEAN countries including Malaysia, Laos, Cambodia & Vietnam.
Experience:
2013 - 2022
2009 - 2013
2008
Education:
1994 - 1996
Sales & Marketing Manager
A marketing expert with a sales achievement record at RM2.5m per month. Currently, he was appointed as Associate Director of Kuala Lumpur City Football Club. He is also involved in the HORECA program that focuses on increasing sales for all Makro Cash & Carry (M) Sdn. Bhd. (FMCG) branches throughout Malaysia. He also has received The Legendary Award from Starbucks International Officer for being the best store in Malaysia.
Experience:
2002 - 2004
2006 - 2009
2007-2007
2009 - 2015
2015 - 2019
2022 - present
Education:
CFO
A financial expert with 30 years of financial and strategy development experiences in services, engineering, construction and mining industries locally and internationally. From 1992 to 2007, he held various accounting positions in MMC/MMCEG Group. From 2007 to 2013, he was the Finance Director for a multinational mining company in Indonesia, PT Koba Tin. He was reporting directly to the President Director and responsible for the overall financial, statutory reporting and IT functions.
Experience:
2006 - 2014
2000 - 2006
1995 - 1999
Education:
1982
1985
1988
Special Project Manager
A registered pharmacist with 15 years of working experience in pharmaceutical regulatory, pharmacy enforcement division and community pharmacy. He is the founder of Pharmacap Group Sdn Bhd, a group of community pharmacist that focus on development of a pharmacy online platform. He is specialised in halal medicine, with extensive experience working with NPRA and Regulatory Pharmacy.
Experience:
5 years
4 years
3 years
Education:
2006
Redeemable Convertible Preference Shares
The Issuer intends to raise up to RM 10,000,000 in this fundraising exercise.
RM 1,000,000
RM 10,000,000
RM 1 per share
1,000,000 shares
10,000,000 shares
RM 2,500
14 working days after the end of the Fundraising Period.
An Investment Agreement (with an Annexed Partnership Agreement) for the subscription of the Shares and subject to review and/or amendment if required or deemed necessary by the Issuer and the ECF Platform.
The information, calculations and remarks expressed on this term sheet or on any other part of the platform are based on information provided, disclosed and presented by the Issuer, Jardin Pharma Berhad to Ata Plus Sdn Bhd, either in part or in whole. Ata Plus disclaims responsibility for the accuracy, completeness and/or validity of these information, and hence will not be held liable for any inaccurate, inappropriate or incomplete information presented on this term sheet or on any other part of the platform subject to the following :
The financial information listed on the deal page is provided by the Issuer; which includes the financial forecasts and projections, the capitalisation table, the term sheet, and management accounts.
The financial forecasts and projections have been prepared by the Issuer based on assumptions that have not been reviewed and certified by an independent certified accountant for its reasonableness
THE ISSUER agrees that; all information concerning the product, business and the assets of THE ISSUER that have been furnished to Ata Plus Sdn Bhd for the purpose of the equity crowdfunding campaign is true, complete, and accurate in all material respects and is not misleading or deceptive whether by inclusion or omission.
Should the Investor require more information, they can do so by contacting Jardin Pharma Berhad directly at jardinpharma.my@gmail.com.
(i) No shares will be alotted or issued based on this document after six months from the closing of the offer period
(ii) This issue, offer or invitation for the offering is a proposal not requiring authorisation of the Securities Commission under section 212(8) of the CMSA 2007
(iii) This document has not been reviewed by the Securities Commission Malaysia. The Securities Commission does not recommend nor assumes responsibility for any information including any statement, opinion or report disclosed in relation to this fund raising exercise and makes no representation as to its accuracy or completeness. The Securities Commission expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the information disclosed.
Redemption Period
The redemption period is 3 years.
Conversion
Conversion rights for tier I & II (“investors”) executable after 5 years (“conversion date”) from the date of issuance (“issue date”) is fixed at 20% ordinary shares of the company valued based on valuation methodology to be determined later.
6. [08.03.2023] Jardin Pharma - eSSM
SSM
f) Draft Audited Report 2022
Financial Account
ATA Plus - refer slide 30 _ 31 (1)
Business Plan
Sign in to access company documents and detailed information
Don't have an account? Register here
View our detailed presentation slides
Min Target
RM 1,000,000
Max Target
RM 10,000,000
Investing in equity crowdfunding involves certain risks that include uncertainty of returns, lack of liquidity, dilution, material events and lack of control. Investments should be done as part of a diversified portfolio. ATA PLUS offers investment opportunities to investors who understands these risks in making their own investment decisions.
PLEASE READ THE FULL RISK WARNING BEFORE DECIDING TO INVEST.
This page is approved as a financial promotion by ATA PLUS Sdn. Bhd., which is authorized and regulated by the Security Commission of Malaysia. Deals that are up for investment are only offered to members of ata-plus.com on the basis of information provided by the companies concerned. ATA PLUS takes no responsibility for this information or for any recommendations or opinions made by the companies. For further information on this, please read our Term of Use.
Min Target
RM 1,000,000
Max Target
RM 10,000,000
Min Investment
RM 2,500